Treatment-related adverse events
| Adverse event . | Grades 1 and 2, no. (%) . | Grades 3 and 4, no. (%) . |
|---|---|---|
| Fatigue | 15 (44) | 12 (35) |
| Dizziness | 20 (59) | 4 (12) |
| Edema | 17 (50) | 0 (0) |
| Skin rash | 14 (41) | 6 (18) |
| Respiratory infection | 13 (38) | 4 (12) |
| Hypoalbuminemia | 8 (24) | 10 (29) |
| Increased creatinine | 17 (50) | 3 (9) |
| Myelosuppression | 20 (59) | 12 (35) |
| Thromboembolic events | 0 (0) | 3 (9) |
| Muscle cramps | 22 (65) | 1 (3) |
| Worsening of PS* | 7 (21) | 9 (26) |
| Adverse event . | Grades 1 and 2, no. (%) . | Grades 3 and 4, no. (%) . |
|---|---|---|
| Fatigue | 15 (44) | 12 (35) |
| Dizziness | 20 (59) | 4 (12) |
| Edema | 17 (50) | 0 (0) |
| Skin rash | 14 (41) | 6 (18) |
| Respiratory infection | 13 (38) | 4 (12) |
| Hypoalbuminemia | 8 (24) | 10 (29) |
| Increased creatinine | 17 (50) | 3 (9) |
| Myelosuppression | 20 (59) | 12 (35) |
| Thromboembolic events | 0 (0) | 3 (9) |
| Muscle cramps | 22 (65) | 1 (3) |
| Worsening of PS* | 7 (21) | 9 (26) |
n = 34 patients.
Performance status by SWOG criteria.